“Dovel Technologies announced today they have been awarded two IDIQs from the Food and Drug Administration (FDA) Center for Biologics Effectiveness and Research (CBER) for the CBER Biologics Effectiveness and Safety (BEST) Initiative. The program will help CBER expand and enhance current capabilities with respect to data sources, infrastructure, methods, and tools and to conduct active surveillance, epidemiologic studies and automated reporting to improve the the safety and efficacy of biologic products including vaccines, blood and blood products, tissues, and advanced therapeutics…”
“Dovel has been awarded two separate IDIQs; Data, Tools and Infrastructure for Surveillance of Biologics as well as Development of New and Innovative Methods for Automated Reporting for CBER-Regulated Biological Products.”
“Dovel secured one of four awards for each of these five-year IDIQs. Each award has a ceiling of $75 million. Dovel is supported by a collaborative team that brings significant breadth and depth including access to leading national data sources of claims and EHR data, biostatistics and epidemiology as well as expertise in machine learning, natural language processing and Artificial Intelligence.”
“The awards expand Dovel’s work with CBER. The company has been supporting the agency’s Laboratory Information Management System (LIMS) development, integration, and deployments since 2011…” Read the full press release here.
Source: Dovel Technologies Awarded Biologics Surveillance IDIQ – October 24, 2018. Dovel Technologies.
